References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2016 Available from: http://www.goldcopd.org/Accessed March 14, 2016
- BarrechegurenMMonteagudoMFerrerJTreatment patterns in COPD patients newly diagnosed in primary care. A population-based studyRespir Med2016111475326758585
- PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- MateraMGRoglianiPCazzolaMQVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20151671079109025843089
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
- ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
- DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
- BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)Int J Chron Obstruct Pulmon Dis20161119320526893551
- WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
- MartinALMarvelJFahrbachKCadaretteSMWilcoxTKDonohueJFThe association of lung function and St. George’s respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisRespir Res2016174027084761
- BanerjiDFedeleMJChenHKimHJDual bronchodilation with QVA149 reduces COPD exacerbations: results from the IGNITE program (OS36: COPD 3)Respirology2013186970
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- NanniniLJPoolePMilanSJKestertonACombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20138CD006826
- DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPLoS One201495e9714924878543
- LeeMCLeeCHChienSCInhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort studyMedicine (Baltimore)20159442e172326496284
- CavkaytarOVuralliDArik YilmazEEvidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid useEur J Pediatr2015174111421143126255048